Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT04374578
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Glycemic variability will be assessed using continuous glucose monitor(CGM) in type 2 diabetic patients who receive dulaglutide 1.5 mg/qw injection for 4 weeks.

Key Dates

Start date
May 8, 2020
Status verified
Jul 2020
Primary completion
Jan 31, 2021
Completion
Jun 30, 2021

Study Design

Enrollment
100 participants (actual)

Primary Outcome Measure

Effect on glycemic variability [ Time Frame: one months ]

Related Studies